指南与共识呼吸衰竭与机械通气重症综合管理与镇静镇痛消化、代谢与肾脏急症

免疫抑制宿主重症肺炎诊断与治疗中国专家共识

[Chinese expert consensus on the diagnosis and treatment of severe pneumonia in immunocompromised hosts].
指南 / 共识 · Zhonghua Jie He He Hu Xi Za Zhi · 2026-01-01
一句话结论中华医学会呼吸病学分会与中国抗癌协会组织多学科专家制定共识,涵盖免疫抑制宿主重症肺炎的14个临床关键问题,采用GRADE分级给出推荐。

免疫抑制宿主感染后进展为重症肺炎的风险显著高于免疫正常人群,且病死率更高,但国内外尚缺乏针对该人群重症肺炎的诊疗指南和专家共识。中华医学会呼吸病学分会联合中国抗癌协会肿瘤呼吸病学分会,组织国内呼吸与危重症和感染领域相关专家制定本共识,包含免疫抑制宿主的定义与分类、重症肺炎诊断和治疗相关的14个临床关键问题。共识采用GRADE框架系统评价证据并形成推荐,旨在规范临床实践、支持循证决策,最终改善中国免疫抑制宿主重症肺炎患者的结局。

要点

  • 免疫抑制宿主的免疫抑制状态分为原发性和继发性,评估应结合基础疾病与可获得的免疫学参数。
  • 免疫抑制宿主重症肺炎按2016年中国社区获得性肺炎(CAP)指南标准诊断,初次诊断时即应评估病情严重程度和免疫状态,该人群住院阈值可适当降低(1C)。
  • 初始经验性抗感染治疗应覆盖耐药革兰阴性菌和革兰阳性菌,存在危险因素时扩大覆盖(1A);呼吸机相关性肺炎(VAP)推荐含β-内酰胺类的联合方案(1A)。
  • 侵袭性肺念珠菌病首选棘白菌素类,适当时可考虑换用唑类(1A);肺移植或造血干细胞移植后短期内出现双肺间质性肺炎者,推荐经验性覆盖巨细胞病毒肺炎(1A)。
  • 不需要立即插管的免疫抑制宿主重症肺炎合并呼吸衰竭,优先选择无创呼吸支持,可选经鼻高流量氧疗(HFNO)或无创正压通气(NPPV)(1A)。

适用人群与场景

  • 免疫抑制宿主:因各种内在或外在因素导致对病原体免疫反应显著减弱或缺失的患者,免疫抑制状态分为原发性和继发性。
  • 免疫抑制宿主重症肺炎合并呼吸衰竭、不需要立即插管的患者,优先选择无创呼吸支持(HFNO或NPPV)(1A)。
  • 肺移植或造血干细胞移植后短期内出现双肺间质性肺炎的患者,推荐经验性覆盖巨细胞病毒肺炎(1A)。

诊断标准与关键阈值

  • 免疫抑制宿主的定义:因各种内在或外在因素导致对病原体免疫反应显著减弱或缺失的患者;免疫抑制状态分为原发性和继发性,评估应结合患者基础疾病与可获得的免疫学参数。
  • 免疫抑制宿主重症肺炎的诊断标准:按2016年中国社区获得性肺炎(CAP)指南所列标准诊断;初次诊断时应评估病情严重程度和免疫状态,以评估风险并指导治疗决策,该人群住院阈值可适当降低(1C)。

处置流程与药物剂量

  • 疑似感染后尽早采样送微生物学检查,采样方式根据患者病情和临床团队经验个体化(1B)。
  • 重症肺炎免疫抑制宿主应在经验性治疗前或同时进行全面的微生物学检测,以尽早明确病原体并指导治疗策略(1A)。
  • 初始经验性治疗应覆盖耐药革兰阴性菌和革兰阳性菌,存在危险因素时扩大覆盖(1A)。
  • 呼吸机相关性肺炎(VAP)推荐含β-内酰胺类的联合方案(1A)。
  • 侵袭性肺念珠菌病首选棘白菌素类治疗,适当时可考虑换用唑类(1A)。
  • 肺移植或造血干细胞移植后短期内出现双肺间质性肺炎者,推荐经验性覆盖巨细胞病毒肺炎(1A)。
  • 经验性治疗的选择应基于免疫缺陷类型和程度、医疗暴露、抗菌药物耐药风险、感染严重程度、微生物学结果、治疗反应及预防策略(1A)。
  • 不需要立即插管的免疫抑制宿主重症肺炎合并呼吸衰竭,优先选择无创呼吸支持,可选HFNO或NPPV(1A);拔管后无NPPV禁忌时可尝试NPPV作为初始策略(1A);气管插管时机和ECMO启动时机通常与免疫正常宿主相同(1A)。

研究设计与关键结果

  • 共识由中华医学会呼吸病学分会与中国抗癌协会肿瘤呼吸病学分会组织呼吸与危重症医学、感染性疾病及相关领域多学科专家组制定,针对免疫抑制宿主重症肺炎的14个临床关键问题,采用GRADE框架系统评价证据并形成推荐。

证据类型、等级与局限

  • 证据类型:专家共识;采用GRADE框架进行证据评价和推荐分级,各推荐条目附有推荐等级(如1A、1B、1C)。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 免疫抑制宿主重症肺炎按2016年中国CAP指南标准诊断,初次诊断时即评估病情严重程度和免疫状态,该人群住院阈值可适当降低(1C)。
  • 免疫抑制宿主重症肺炎应在经验性治疗前或同时进行全面的微生物学检测(1A),并尽早采样送检(1B)。
  • 不需要立即插管的免疫抑制宿主重症肺炎合并呼吸衰竭优先选择无创呼吸支持,可选HFNO或NPPV(1A);拔管后无NPPV禁忌时可尝试NPPV作为初始策略(1A)。
  • 免疫调节治疗是免疫抑制宿主重症肺炎治疗的重要组成部分,应评估免疫状态以指导个体化免疫调节策略(1B)。

指南或共识出处

  • 中华医学会呼吸病学分会、中国抗癌协会肿瘤呼吸病学分会组织制定的《免疫抑制宿主重症肺炎诊断与治疗中国专家共识》。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

The population of immunocompromised hosts has steadily increased in recent years. Clinical evidence indicates that these individuals are at a significantly higher risk of developing severe pneumonia following infection, with the mortality rates markedly higher than those observed in immunocompetent individuals. However, there is currently a lack of specific national or international guidelines or expert consensus addressing the management of severe pneumonia in this population. To address this unmet need, the Chinese Thoracic Society (CTS) of the Chinese Medical Association and the Oncology Respiratory Disease Committee of China Anti-Cancer Association (CACA) convened a multidisciplinary panel of experts from respiratory and critical care medicine, infectious diseases, and related fields in China to develop the present consensus.This consensus addresses 14 key clinical questions, covering topics such as the definition and classification of immunocompromised hosts, and the diagnosis and treatment of severe pneumonia in this high-risk group. The panel systematically reviewed evidence and formulated recommendations using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. The resulting consensus aims to standardize clinical practice, support evidence-based decision-making, and eventually improve outcomes for immunocompromised patients with severe pneumonia in China.Question 1: Definition and classification of immunocompromised Hosts.Recommendation 1: An immunocompromised host is defined as a patient with a significantly weakened or absent immune response to pathogens owing to various intrinsic or extrinsic factors. The immunocompromised status is categorized as either primary or secondary. This assessment should integrate the patient's underlying conditions with available immunological parameters.Question 2: What are the diagnostic criteria for severe pneumonia in immunocompromised hosts, and which indicators are recommended for severity assessment?Recommendation 2: Severe pneumonia in immunocompromised hosts is diagnosed based on the criteria outlined by the 2016 Chinese guidelines for community-acquired pneumonia (CAP). Disease severity and immune status should be assessed at initial diagnosis to evaluate risk and guide treatment decisions. Hospitalization thresholds may be appropriately reduced in this population (1C).Question 3: What are the diagnostic and therapeutic workflows for severe pneumonia in immunocompromised hosts, and how should infectious pneumonia be distinguished from non-infectious pulmonary infiltrates?Recommendation 3: A multidimensional approach is recommended for differentiating severe pneumonia from non-infectious pulmonary infiltrates in immunocompromised hosts. Clinical, radiological, and microbiological data should be integrated. When necessary, histopathological biopsy and/or multidisciplinary team (MDT) consultation should be performed. The detailed diagnostic and therapeutic workflow are illustrated in Figure 1 (1A).Question 4: What are the major pathogens causing pneumonia in immunocompromised hosts, and how does pathogen distribution differ across immunosuppressive states?Recommendation 4: The core pathogens causing pneumonia in immunocompromised hosts are usually similar to those in immunocompetent hosts. However, pathogen distribution is more diverse, with immunocompromised hosts showing a higher prevalence of opportunistic pathogens and mixed infections (Table 5 and Figure 1A).Question 5: What are the recommended timings and methods for obtaining clinical specimens from immunocompromised hosts?Recommendation 5: High-quality clinical specimens are necessary for etiological diagnosis. Once infection is suspected, early sampling for microbiological testing is recommended. The sampling approach should be individualized based on the patient's condition and the clinical team's experience (1B).Question 6: How to choose diagnostic methods for pathogen identification in immunocompromised hosts with pneumonia?Recommendation 6: For immunocompromised hosts with severe pneumonia, comprehensive microbiological testing should be performed before or concurrently with empirical therapy to identify pathogens as early as possible and guide treatment strategies (1A).Question 7: What are the principles of anti-infective therapy for severe pneumonia in immunocompromised hosts?Recommendation 71. Initial empirical therapy should target drug-resistant Gram-negative and Gram-positive bacteria, with expansion of coverage when risk factors are present (1A).2. For ventilator-associated pneumonia (VAP), combination regimens that include β-lactams are recommended (1A).3. Echinocandins are preferred for treating invasive pulmonary candidiasis, and a switch to azoles may be considered when appropriate (1A).4. Empirical coverage for cytomegalovirus pneumonia is recommended for patients developing bilateral interstitial pneumonia shortly after lung transplantation or hematopoietic stem cell transplantation (1A).Question 8: What factors should be considered when selecting empirical anti-infective therapy for severe pneumonia in immunocompromised hosts?Recommendation 8: Empirical therapy should be selected based on the type and degree of immunodeficiency, healthcare exposure, risk of antimicrobial resistance, severity of infection, microbiological findings, treatment response, and preventive strategies (1A).Question 9: What are the recommended treatment durations for different pathogens in severe pneumonia among immunocompromised hosts?Recommendation 9: Treatment duration primarily depends on clinical presentation, radiographic changes, severity of infection, pathogen resistance profile, and the immune status of patients (1A).Question 10: Which respiratory support strategies should be prioritized for immunocompromised hosts with severe pneumonia complicated by respiratory failure?Recommendation 10: Noninvasive respiratory support is preferred for immunocompromised hosts with severe pneumonia and respiratory failure who do not require immediate intubation. High-flow nasal oxygen (HFNO) or noninvasive positive-pressure ventilation (NPPV) may be selected (1A).Question 11: When is tracheal intubation most appropriate for immunocompromised hosts with severe pneumonia?Recommendation 11: The timing of tracheal intubation in immunocompromised hosts is usually similar to that in immunocompetent hosts (1A).Question 12: When should extracorporeal membrane oxygenation (ECMO) be initiated in immunocompromised hosts with severe pneumonia and respiratory failure?Recommendation 12: The timing of ECMO initiation should be determined based on the same criteria as those used for immunocompetent hosts (1A).Question 13: For immunocompromised patients with severe pneumonia and respiratory failure, is early extubation followed by NPPV or HFNO a viable option?Recommendation 13: Early extubation followed by NPPV or HFNO can be actively considered for immunocompromised patients with severe pneumonia complicated by respiratory failure. In the absence of contraindications to NPPV, NPPV may be attempted as the initial post-extubation strategy (1A).Question 14: What recommendations are there for immunomodulatory therapy in immunocompromised hosts with severe pneumonia?Recommendation 14: Immunomodulation is an important component of therapy in immunocompromised hosts with severe pneumonia. Immune status should be assessed to guide individualized immunoregulatory strategies (1B).

近年来,免疫抑制宿主在临床实践中日益常见,大量临床研究表明,免疫抑制宿主感染后进展为重症肺炎的风险显著高于免疫正常人群,且病死率更高。由于目前国内外尚缺乏针对免疫抑制宿主重症肺炎的诊疗指南和专家共识,中华医学会呼吸病学分会联合中国抗癌协会肿瘤呼吸病学分会,组织国内呼吸与危重症和感染领域相关专家制定了本共识。本共识包含免疫抑制宿主的定义与分类、免疫抑制宿主重症肺炎的诊断和治疗相关的14个临床关键问题,为免疫抑制宿主重症肺炎的规范化诊疗提供建议。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

参考来源

  1. [Chinese expert consensus on the diagnosis and treatment of severe pneumonia in immunocompromised hosts]. Zhonghua Jie He He Hu Xi Za Zhi. 2026. PMID: 41629088. doi:10.3760/cma.j.cn112147-20250729-00449

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。